EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dendrimer Conjugates with PD‐L1‐Binding Peptides Enhance In Vivo Antitumor Immune Response

DaWon Kim iD, Jin Woong Lee iD, Piper A Rawding iD, Mari Iida iD, Carter Kim, Kourtney L Kostecki iD, Michael J Poellmann iD, Bridget Crossman iD, Ashley S Liu, YoungSoo Kim iD, Deric L Wheeler iD, Seungpyo Hong iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202500551 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von DaWon Kim und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Division, University of Wisconsin School of Pharmacy, Madison, WI, 53705, USA. Hauptthemen laut MEDLINE: Dendrimers, B7-H1 Antigen, Peptides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, Department of Defense (DOD) CDMRP, University of Wisconsin (UW) Head & Neck SPORE from National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Peptides are an emerging class of biologics for cancer immunotherapy; however, their clinical translation is hindered by poor binding kinetics, bioavailability, and short plasma half‐life compared to their corresponding antibodies. Nanoparticles present potential solutions but face scale‐up difficulties due to complexity. Here, a translatable, modular nanoparticle scaffold is presented for peptide‐based immune checkpoint inhibitors (ICIs). This platform is based on a simple structure of generation 7 (G7) poly(amidoamine) (PAMAM) dendrimers conjugated with engineered peptides (dendrimer‐peptide conjugates, DPCs). DPCs functionalized with multiple copies of a programmed death‐ligand 1 (PD‐L1)‐binding peptide exhibited significantly enhanced avidity‐based binding kinetics and in vitro specificity, in addition to the substantially prolonged plasma half‐life in vivo. Notably, a series of in vivo experiments revealed that DPCs displayed selective tumor accumulation and high efficacy, without apparent toxicity, when applied to a syngeneic mouse model bearing mouse oral carcinoma (MOC1) tumors. The results indicate that the DPC platform significantly improves the antagonistic effect and in vivo behaviors of the PD‐L1‐binding peptides, which can be potentially applied to virtually any peptide‐based ICIs. The DPC platform's simplicity and modular nature will likely increase the potential of its clinical translation and ultimately enable precision/personalized cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DendrimersB7-H1 AntigenPeptidesAnimalsMiceCell Line, TumorHumansImmunotherapyNanoparticlesFemaleMice, Inbred C57BL

Stichwörter der Autor:innen

Cancer immunotherapyPD‐L1‐ binding peptidedendrimerimmune checkpoint inhibitormultivalent biding

Substanzen

DendrimersB7-H1 AntigenPeptides

Autor:innen und Institutionen

  • Pharmaceutical Sciences Division, University of Wisconsin School of Pharmacy, Madison, WI, 53705, USA.
  • Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, 53705, USA.
  • Department of Pharmacy, Yonsei University, Incheon, 21983, South Korea.
  • Yonsei Frontier Lab, Yonsei University, Seoul, 03722, South Korea.
  • University of Wisconsin Carbone Cancer Center, Madison, WI, 53705, USA.
  • Wisconsin Center for NanoBioSystems, University of Wisconsin, Madison, WI, 53705, USA.

ORCID-Profile: DaWon Kim, Jin Woong Lee, Piper A Rawding, Mari Iida, Kourtney L Kostecki, Michael J Poellmann, Bridget Crossman, YoungSoo Kim, Deric L Wheeler, Seungpyo Hong

Förderung

  • NCI NIH HHS
  • Department of Defense (DOD) CDMRP
  • University of Wisconsin (UW) Head & Neck SPORE from National Institutes of Health (NIH)
  • National Science Foundation (NSF)

Zitieren

APA

Kim, D., Lee, J. W., Rawding, P. A., Iida, M., Kim, C., Kostecki, K. L., Poellmann, M. J., Crossman, B., Liu, A. S., Kim, Y., Wheeler, D. L., & Hong, S. (2025). Dendrimer Conjugates with PD‐L1‐Binding Peptides Enhance In Vivo Antitumor Immune Response. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202500551

Vancouver

Kim D, Lee JW, Rawding PA, Iida M, Kim C, Kostecki KL, et al. Dendrimer Conjugates with PD‐L1‐Binding Peptides Enhance In Vivo Antitumor Immune Response. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202500551

BibTeX
@article{Kim2025,
  author = {Kim, DaWon and Lee, Jin Woong and Rawding, Piper A and Iida, Mari and Kim, Carter and Kostecki, Kourtney L and Poellmann, Michael J and Crossman, Bridget and Liu, Ashley S and Kim, YoungSoo and Wheeler, Deric L and Hong, Seungpyo},
  title = {Dendrimer Conjugates with PD‐L1‐Binding Peptides Enhance In Vivo Antitumor Immune Response},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202500551}
}
Kostenlos starten →